SCHEMBL5896384

SCHEMBL5896384

Cc1ccc(Oc2cccc(/C=C(/NC(=O)c3ccccc3)C(=O)O)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
ALDH1A1 P00352 5/20 0.60
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPK14 Q16539 1/20 0.47
MMP13 P45452 1/20 0.47
ATM Q13315 1/20 0.46
PGR P06401 1/20 0.46
ASF1A Q9Y294 1/20 0.46
GCK P35557 1/20 0.46
HDAC8 Q9BY41 1/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896393 1.00 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5896370 1.00 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5895023 0.93 LMNA (0.76) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5895003 0.93 LMNA (0.76) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5895012 0.93 LMNA (0.76) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5896358 0.91 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5896366 0.91 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5896350 0.91 LMNA (0.70) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5894898 0.89 LMNA (0.67) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5894883 0.89 LMNA (0.67) LMNAALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 LMNA 4118/4885ALDH1A1 832/4885MEN1 4847/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI LMNA 4047/4885ALDH1A1 1400/4885MEN1 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.